The Van Gogh Study: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 as Adjunct Therapy to L-dopa in Patients with Parkinson's Disease Experiencing Motor Fluctuations.

Trial Profile

The Van Gogh Study: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 as Adjunct Therapy to L-dopa in Patients with Parkinson's Disease Experiencing Motor Fluctuations.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Pardoprunox (Primary) ; Pramipexole
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms The Van Gogh Study
  • Sponsors Solvay Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2017 This trial has been discontinued in Hungary, according to European Clinical Trials Database.
    • 14 Mar 2017 Status changed from discontinued to completed.
    • 23 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top